Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies.

Intest Res · 2017 · PMC5683978 · PMID 29142515

Europe PMC DOI

hedged sentence

0.0350

closest p · 0.7× alpha

0.0350

boldest claim

The sentences

nominally significantP =0.035actually significant

In the overall study population, the proportion of patients in corticosteroid-free remission at week 44 was significantly greater in the q8w group ( P =0.004) and nominally significant in the q12w group ( P =0.035; as per hierarchical testing procedure) than with placebo ( Supplementary Fig. 4 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.